Entrapped doxorubicin nanoparticles for the treatment of metastatic anoikis-resistant cancer cells

► Doxorubicin encapsulating human serum albumin nanoparticles (HSA + DOX NPs) were fabricated to confirm the benefit of nanoparticles at the treatment of anoikis-resistant breast cancer cells. ► HSA + DOX NPs were more cytotoxic to anoikis-resistant cancer cells than free doxorubicin. ► HSA + DOX NPs delivered more doxorubicin into cells compared to the free doxorubicin by bypassing the drug efflux pump systems of anoikis-resistant cancer cells.